Whalesbook
ICICI Securities maintains a BUY rating on Alkem Laboratories with an increased target price of INR 6,600. The company reported strong Q2FY26 results, driven by a 12% year-on-year growth in India business and a 28% rise in US revenue, aided by new launches. EBITDA margins improved due to lower R&D and operating leverage. However, management remains cautious about future margins, expecting them in the 19.5-20% range for FY26.